Karolinska Development :: View by company A-Z

Akinion Pharmaceuticals AB Akinion Pharmaceuticals is developing a small molecule kinase inhibitor for the treatment of leukemia and other types of cancer. www.akinion.com		Aprea AB Aprea is developing pharmaceuticals that reactivates the tumor suppressor protein p53, which is impaired in many instances of cancer. www.aprea.com		Athera Biotechnologies AB Athera develops products for the risk assessment and treatment of cardiovascular disease related to inflammatory and immunological mechanisms. www.athera.se
Axelar AB Axelar is in clinical development of its lead drug candidate AXL1717 that inhibits the Insulin-like Growth Factor 1 receptor (IGF-1) for the treatment of cancer. www.axelar.se		BioChromix AB BioChromix is developing diagnostic tests for early detection of Alzheimer's disease and identification of biomarkers associated with the disease. www.biochromix.com		BioChromix Pharma AB BioChromix Pharma develops new drugs for the treatment of neurodegenerative diseases, such as Alzheimer’s disease. www.biochromixpharma.com
Biosergen AS Biosergen develops new pharmaceuticals for the treatment of systemic fungal infections. www.biosergen.no		Clanotech AB Clanotech is developing small molecule inhibitors of alpha5beta1-integrin involved in adverse blood vessel formation that occurs in diseases of the eye. www.clanotech.se		Dilafor AB Dilafor is developing pharmaceuticals against protracted labor based on modified heparin. www.dilafor.com
Dilaforette AB Dilaforette is developing a heparin analogue, sevuparin, for the treatment of severse malaria that prevents infected cells from obstructing blood vessels. www.dilaforette.se		KDev Oncology AB GliGene is developing small molecule antagonists to the Sonic Hedgehog signalling pathway involved in tumor proliferation.		Inhalation Sciences Sweden AB Inhalation Sciences Sweden has developed a research platform that can provide early stage pharmacokinetic and dynamic data for very early selection of drug candidates. www.inhalation.se
KDev Oncology AB KDev Oncology is Karolinska Development's holding company that coordinates and utilizes synergies between companies involved in cancer therapy R&D.		Lipidor AB Lipidor develops innovative technologies for lipid-based topical pharmaceutical delivery. www.lipidor.se		NeoDynamics AB NeoDynamics works with new devices for minimally invasive diagnostics and the treatment of early-stage breast cancer. www.neodynamics.se
NovaSAID AB NovaSAID is developing new drugs for the treatment of pain relief associated with inflammatory diseases, such as rheumatoid arthritis and osteoarthritis. www.novasaid.se		Oss-Q AB Oss-Q is developing pioneering implants for bone healing with an initial focus on skull surgery. www.oss-q.com		Pergamum AB Pergamum runs three development programs. DPK-060 is being developed in clinical Phase II for treatment of inflammatory and infectious skin diseases, PXL01 is a candidate drug in Phase II against post-surgical adhesion formation in connection with surgery. www.pergamum.com
Pharmanest AB Pharmanest is developing clinical stage pain relief during gynecological procedures. www.pharmanest.se		Promimic AB Promimic develops and markets a nano-based surface applied to dental and bone implants for improved integration to bone and soft tissue www.promimic.com		Umecrine AB Umecrine develops pharmaceuticals against diseases and conditions caused by natural CNS-active sex and stress hormones, known as the GABA steroids. www.umecrine.se
Umecrine Cognition AB Umecrine Cognition develops pharmaceuticals against mild Alzheimer’s disease and mild cognitive disorders. www.umecrine.se		Umecrine Mood AB Umecrine Mood is developing pharmaceuticals against premenstrual dysphoric disorder (PMDD) through modulation of the influence of GABA steroids on the brain. www.umecrine.se		XSpray Microparticles AB XSpray Microparticles helps pharmaceutical companies with the formulation of challenging drug substances based on its proprietary, scalable particle manufacturing technology. www.xspray.com

Financial/Passive Investments

BioArctic Neuroscience AB BioArctic Neuroscience develops new treatment methods and diagnostic tools for Alzheimer’s disease and other neurodegenerative diseases. www.bioarctic.se		CytoGuide ApS Cytoguide develops pharmaceuticals that selectively bind receptors on cells in inflamed tissue. www.cytoguide.dk		Laurantis Pharma Oy Laurantis Pharma develops new drugs against cancer, lymphedema and eye disease. www.pergamum.com
NephroGenex Inc. NephroGenex is developing a drug candidate against diabetic nephropathy and other renal disorders. www.nephrogenex.com

PDF